Callisto’s Cancer Drug Atiprimod to Be Presented at Scientific Conference on Cancer Drugs and Angiogenesis
NEW YORK, Jan. 24 /PRNewswire-FirstCall/ — Callisto Pharmaceuticals, Inc. (AMEX: KAL)(Frankfurt”>CA4), a biopharmaceutical company primarily focused on the development of drugs to treat cancer and other major health threats, today announced that Dr. Kunwar Shailubhai will be giving an invited presentation on Atiprimod, the Company’s anti-cancer drug candidate, at the GTCbio conference on February 8-9,…